8-K - Reviva Pharmaceuticals Holdings, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Reviva Pharmaceuticals reported a FY2025 net loss of $19.9 million with cash of $14.4 million, while securing $29 million in equity financings and planning a mid-2026 Phase 3 trial (RECOVER-2) for brilaroxazine following FDA guidance.

Key Takeaways

1FY2025 net loss was $19.9 million ($5.48 per share) compared to FY2024 net loss of $29.9 million ($17.73 per share)

2Cash and cash equivalents totaled $14.4 million as of December 31, 2025

3Completed three public equity offerings raising total gross proceeds of $29.0 million ($10M June 2025, $9M September 2025, $10M March 2026)

4Current cash position of approximately $23 million expected to fund operations into Q1-2027

5FDA recommended a second Phase 3 clinical trial (RECOVER-2) for brilaroxazine prior to NDA submission

6Plans to initiate RECOVER-2 registrational trial in mid-2026 with patient enrollment beginning Q3 2026

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. | Results of Operations and Financial Condition. | |---|---| Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on March 30, 2026, d

Financial Results

7.01

. | Regulation FD Disclosure. | |---|---| See “Item 2.02 Results of Operations and Financial Condition” above. The information in this Current Report on Form 8

Regulation Fd

9.01

. | Financial Statements and Exhibits. | |---|---| (d) The following exhibit is furnished with this report: | Exhibit No. | | Description | |---|---|---| | 99.1

Exhibits Only

Source Document

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Net Loss	$-19.9M	GAAP	$-29.9M
Net Loss Per Share	$-5.48	GAAP	$-17.73
Research and Development Expenses	$11.7M	GAAP	$22.9M
General and Administrative Expenses	$8.5M	GAAP	$7.9M

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1